Genprex, Inc.
corporate_fare Company Profile
Genprex, Inc. (NASDAQ:GNPX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for GNPX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for GNPX spans 10-Q, 8-K, S-3, DEF 14A.
Recent high-impact activity:
- Genprex Q3 10-Q: Going Concern Reiterated Despite $15.3M Cash After $18.7M ATM Raise
- Genprex 10-Q: Persistent Material Weaknesses, Going Concern Reiterated, and New Nasdaq MVLS Delisting Risk
- Genprex Taps Roche Diagnostics to Validate TROP2 Biomarker for NSCLC Trials
- Genprex Secures Nasdaq Exception to Regain Compliance, Must Maintain $1.00 Bid Price Through December 7
- Genprex Sets 1:22 Reverse Split Effective July 16 to Fight Nasdaq Delisting
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 123,259 shares in GNPX as of the October 30, 2026 settlement, a 1.3% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 31.7% of GNPX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for GNPX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.
New Universal Shelf Registration · Replaces and Expands Prior Shelf
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →